ReviewFuture oncology (London, England)2010
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?
Review in Future oncology (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy.International journal of nanomedicine · 2026Review
- Engineered microorganism-based delivery systems for targeted cancer therapy: a narrative review.Biomaterials translational · 2022Review
- Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Frontiers in immunology · 2022Review
- Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.Frontiers in oncology · 2022Review
- Oncolytic herpes simplex virus infects myeloma cellsMolecular therapy oncolytics · 2021Article
- Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.Journal of the Royal Society, Interface · 2021Article
- Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.Molecular therapy oncolytics · 2019Article
- Oncolytic herpes simplex virus and immunotherapy.BMC immunology · 2018Review
- Please stand by: how oncolytic viruses impact bystander cells.Future virology · 2018Review
- Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.Viruses · 2018Article
- Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.Expert opinion on orphan drugs · 2016Article
- Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.Therapeutic delivery · 2015Review
- Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Molecular therapy oncolytics · 2015Article
- Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy.Oncolytic virotherapy · 2015Review
- Promising oncolytic agents for metastatic breast cancer treatment.Oncolytic virotherapy · 2015Review
- Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.PloS one · 2014Article
- Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.Human gene therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Despite aggressive treatments, including chemotherapy and radiotherapy, cancers often recur owing to resistance to conventional therapies. Oncolytic viruses such as oncolytic herpes simplex virus (oHSV) represent an exciting biological approach to cancer therapy. A range of viral mutations has been engineered into HSV to engender oncolytic activity. While oHSV as a single agent has been tested in a number of cancer clinical trials, preclinical studies have demonstrated enhanced efficacy when it is combined with cytotoxic anticancer drugs. Among the strategies that will be discussed in this article are combinations with standard-of-care chemotherapeutics, expression of prodrug-activating enzymes to enhance chemotherapy and small-molecule inhibitors. The combination of oHSV and chemotherapy can achieve much more efficient cancer cell killing than either single agent alone, often through synergistic interactions. This can be clinically important not just for improving efficacy but also for permitting lower and less toxic chemotherapeutic doses. The viral mutations in an oHSV vector often determine the favorability of its interactions with chemotherapy, just as different cancer cells, due to genetic alterations, vary in their response to chemotherapy. As chemotherapeutics are often the standard of care, combining them with an investigational new drug, such as oHSV, is clinically easier than combining multiple novel agents. As has become clear for most cancer therapies, multimodal treatments are usually more effective. In this article, we will discuss the recent progress of these combinatorial strategies between virotherapy and chemotherapy and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.